Activators of Angiogenesis and Cardiovascular Diseases. Results of Study of Blood Levels of Vascular Endothelial Growth Factor and Angiopoetin-2 in Patients with Essential Hypertension
Keywords:essential hypertension, angiogenesis, vascular endothelial growth factor, angiopoetin-2, inflammation
Blood levels of vascular endothelial growth factor and angiopoetin-2, powerful activators of angiogenesis with proinflammatory activity were studied in hypertensive patients. Significantly higher vascular endothelial growth factor and angiopoetin-2 blood levels have been determined in hypertensive patients compared to normotensive control subjects. The blood levels of angiopoetin-2 were found to be enhanced in hypertensive patients while deterioration of essential hypertensive and at presence of such metabolic disorders as abdominal obesity, fasting hyperglycemia, glucose intolerance, hyperuricemia and combined dyslipidemia. Vascular endothelial growth factor blood levels were higher in hypertensive patients with stable angina pectoris compared to the patients without angina pectoris. The data obtained indicate an important role of angiogenesis activation in the development of essential hypertension and its cardiovascular complications.
Гавриленко Т.И., Рыжкова Н.А., Пархоменко А.Н. Сосудистый эндотелиальный фактор роста в клинике внутренних заболеваний и его патогенетическое значение // Укр. кард. журнал. — 2011. — № 4. — С. 87-95.
Серцево-судинні захворювання. Рекомендації з діагностики, профілактики та лікування // За ред. В.М. Коваленка, М.І. Лутая. — К.: Моріон, 2011. — 400 с.
Borona E., Targher G., Alberiche M. et al. Homeostasis Model Assessment Closely Mirrors the Glucose Clamp Technique in the Assessment of Insulin Sensitivity // Diabet. Care. — 2000. — Vol. 23. — P. 57-64.
Chen C.H., Walterscheid J.P. Plaque angiogenesis versus compensatory arteriogenesis in atherosclerosis // Circ. Res. — 2006. — Vol. 99. — P. 787-789.
2013 ESH/ESC Guidelines for management of arterial hypertension // J. of Hypertension. — 2013. — № 31. — Р. 1281-1357.
Fiedler U., Reiss Y., Scharpfenecker M. et al. Angiopoetins: a link between angiogenesis and inflammation // Trend. Immunol. — 2006. — Vol. 27. — P. 552-558.
Hiyama T., Tanaka T., Endo S. et al. Angiogenesis in atherosclerotic plaque obtained from carotid endarterectomy: association between symptomatology and plaque morphology // Neurol. Med. Chir. — 2010. — Vol. 50. — P. 1056-1061.
Holash J., Davis S., Papadopoulos N. VEGF-Trap: A VEGF blocker with potent antitumor effects // PNAS. — 2002. — Vol. 99, № 17. — P. 1393-1398.
Hughes C.C. Endothelial-stromal interaction in angiogenesis // Curr. Opin. Hematol. — 2008. — Vol. 15. — P. 204-209.
Iribarren C., Phelps B.H., Darbinian J.A. et al. Circulating angiopoietins-1 and -2, angiopoietin receptor Tie-2 and vascular endothelial growth factor-A as a biomarkers of acute myocardial infarction: a prospective nested case-control study // BMS Cardivasc. Disord. — 2011. — Vol. 11, № 31. — Р. 11-31.
Korff T., Ernst E., Nobiling R. et al. Angiopoetin-1 mediates inhibition of hypertension-induces release of angiopetin-2 from endothelial cells // Cardiovascular Research. — 2012. — Vol. 94. — P. 510-518.
Khurana R., Simons M., Martin G. et al. Role of angiogenesis in cardiovascular disease: a critical appraisal // Circulation. — 2005. — Vol. 112. — P. 1813-1824.
Libby P., Ridker P.M., Hansson G.K. Progress and challenges in translating the biology of atherosclerosis // Nature. — 2011. — Vol. 473. — P. 317-332.
Lieb W., Safa R., Benjamin E.J., Xanthakis V. et al. Vascular endothelial growth factor, its soluble receptor, and hepatocyte growth factor: clinical and genetic correlates and association with vascular function // European Heart Journal. — 2009. — Vol. 30. — Р. 1121-1127.
Steeghs N., Gelderblom H., Roodt J.O. et al. Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor // Clin. Cancer Res. — 2008. — Vol. 14. — P. 3470-3476.
Struijker-Boudier H.A.J., Agabiti-Rosei E. The microcirculation and the haemodynamics of hypertension // ESH Clinical Practice Newsletters. — 2011. — P. 67-68.
Zachary I., Morgan R.D. Therapeutic angiogenesis for cardiovascular disease: biological context, challenges, prospects // Heart. — 2011. — Vol. 97. — P. 181-189.
Zhang W., Doherty M., Pascual E. et al. EULAR evidence based recommendations for gout. Part I: diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT) // Ann. Rheum. Dis. — 2006. — Vol. 65. — P. 1301-1311.
Zhang J., Silva T., Yarivinsky T. et al. VEGF Blockade inhibits lymphocyte recruitment and ameliorates immune-mediated vascular remodeling // Circ. Res. — 2010. — Vol. 107. — P. 408-417.
Copyright (c) 2017 HYPERTENSION
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our edition uses the copyright terms of Creative Commons for open access journals.
Authors, who are published in this journal, agree with the following terms:
- The authors retain rights for authorship of their article and grant to the edition the right of first publication of the article on a Creative Commons Attribution 4.0 International License, which allows others to freely distribute the published article, with the obligatory reference to the authors of original works and original publication in this journal.
- Directing the article for the publication to the editorial board (publisher), the author agrees with transmitting of rights for the protection and using the article, including parts of the article, which are protected by the copyrights, such as the author’s photo, pictures, charts, tables, etc., including the reproduction in the media and the Internet; for distributing; for the translation of the manuscript in all languages; for export and import of the publications copies of the writers’ article to spread, bringing to the general information.
- The rights mentioned above authors transfer to the edition (publisher) for the unlimited period of validity and on the territory of all countries of the world.
- The authors guarantee that they have exclusive rights for using of the article, which they have sent to the edition (publisher). The edition (the publisher) is not responsible for the violation of given guarantees by the authors to the third parties.
- The authors have the right to conclude separate supplement agreements that relate to non-exclusive distribution of their article in the form in which it had been published in the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
- The policy of the journal permits and encourages the publication of the article in the Internet (in institutional repository or on a personal website) by the authors, because it contributes to productive scientific discussion and a positive effect on efficiency and dynamics of the citation of the article.
- The rights to the article are deemed transferred by the authors to the edition (the publisher) since the moment of the publication of the article in the printed or electronic version of journal.